Palatin Technologies Inc PTNT / BLAST Stock

Overview Charts & Stats for the Selected Time Period

This overview page provides a quick summary of the selected assets, including their latest prices, price changes, market capitalization changes, and more.

Settings

Asset PTNT / BLAST

Latest Price 31,874.6

Price Change % Calculating...

Price Change X Calculating...

Up Days Calculating...

Down Days Calculating...

Avg Up Day % Calculating...

Avg Down Day % Calculating...

Median Up Day % Calculating...

Median Down Day % Calculating...

Volatility % 64.47%

Win Rate % 51.1%

CAGR % +3,201,232,018.97%

Best Day % +434.63%

Worst Day % -17.76%

Max Drawdown % -27.70%

Period High 30,936.05

Period Low 3,674.11

From High % +0.0%

From Low % +742.0%

Sharpe Ratio 0.17

Days >Avg % 67.4%

Total Volume 1,384,447,022

Volume: 2026-02-17

Aggregate Volume: 46 Days

Price Chart Percentage Gains

The price chart compares the percentage returns for each asset in the given time period. Each starts out at 0% at the x axis left most position.

Price Overlay ChartPercentage Gains

The overlay price chart displays the price movements of each asset over the selected period, using individual y-axes for each. This allows for an easy comparison of assets with different magnitudes, making it great for identifying correlations.

Volume Chart Daily Volume

This volume chart shows the daily volume for each asset.

Learn More

This page just gave you an overview, you might also want to check out the comprehensive stats, historical, correlation, volatility, and price projection pages.

What is Palatin Technologies Inc?

Palatin Technologies Inc. is a biopharmaceutical company focused on developing new treatments for unmet medical needs. The company operates within the biotechnology and pharmaceutical industry, concentrating on therapies that target melanocortin receptors. These receptors play a role in various physiological processes, including inflammation, immune response, and energy balance. Palatin's lead product candidate, PL9643, is an orally administered drug being investigated for the treatment of dry eye disease. The company also has other drug candidates in its pipeline targeting conditions such as inflammatory diseases and obesity. Palatin's strategy involves leveraging its proprietary melanocortin receptor technology platform to discover and develop novel therapeutics. They aim to address diseases where current treatment options are limited or have significant side effects. The company seeks to advance its pipeline through clinical development and potential commercialization, either independently or through strategic partnerships.

🤖 AI Analysis

Model:

Ask me anything about the data on this page. I can help explain metrics, identify patterns, or answer specific questions.

Data sources

Trade hundreds of crypto perpetual futures